News
-
wAIHA | Sovleplenib Demonstrates Positive Phase III Clinical Results
wAIHA is a rare autoimmune disorder in which the immune system produces antibodies that mistakenly target and destroy red blood cells, leading to anemia and significant clinical burden. The…
Read More » -
THALASSAEMIA IN THE AMERICAS | New TIF White Paper Calls for Coordinated Action and Equity in Care
Developed in the context of the 1st TIF Pan-American Conference on Thalassaemia and Other Haemoglobin Disorders, held in Washington, D.C. in July 2025, this publication provides the first region-wide, evidence-based…
Read More » -
THE MENA THALASSAEMIA EXPERIENCE: A Two-Day, In-Person Masterclass
IMPORTANT: In light of the current unrest in the Middle East and the evolving regional situation, this masterclass is postponed until further notice. The safety and well-being of all participants,…
Read More » -
U.S. EXIT FROM WHO | Implications for Global Health Cooperation and Preparedness
The U.S. government said the decision was based on concerns about how the WHO handled previous global health emergencies, particularly the COVID-19 pandemic. According to U.S. officials, the organization did…
Read More » -
SICKLE CELL DISEASE | Alzheimer’s Drug Demonstrates Potential Therapeutic Benefit
The study explores the potential of memantine, a medication that has been safely used for many years in the treatment of Alzheimer’s disease. Researchers investigated whether this well-known, affordable drug…
Read More » -
FDA APPROVES AQVESME™ (mitapivat) | First Oral Therapy for Anaemia Across All Forms of Thalassaemia
This regulatory decision marks a landmark milestone in the management of thalassaemia, as AQVESME is now the first and only therapy approved in the United States indicated for treating anaemia…
Read More » -
PUTTING PATIENTS FIRST IN CLINICAL RESEARCH | New EU Recommendations to Reduce Trials Bureaucracy
As Prof. Martin Dreyling, Chair of the Coalition for Reducing Bureaucracy, explains: “The current safety requirements for investigators are disproportionately burdensome, to the point that they may obscure relevant safety…
Read More » -
EU AGREES LANDMARK REFORM OF PHARMACEUTICAL LEGISLATION | What It Means for Patients and Public Health
This milestone agreement — part of what has been referred to as the “pharma package” — was negotiated between the European Commission, the European Parliament, and the Council of the…
Read More » -
-
1st TIF NURSING WORKSHOP ON HAEMOGLOBINOPATHIES | 29-30 November 2025
📌 Workshop Title: 1st TIF Nursing Workshop on Haemoglobinopathies 📌 Date & Venue: Saturday & Sunday, 29-30 November 2025 | Titania Hotel, Athens, Greece Overview: This landmark workshop represents…
Read More »